599 |
Boston Scientific DES - Current & Future Perspectives |
Keith D. Dawkins |
May. 13. 09 |
598 |
SYNTAX - Data Synthesis and Clinical Recommendations |
Patrick W. Serruys |
May. 13. 09 |
597 |
The Role of Triple Antiplatelet Therapy in Patients with High Risk |
Young-Hoon Jeong |
May. 13. 09 |
596 |
Tailoring Treatment to Risk in Antiplatelet Therapy |
Alexandra J. Lansky |
May. 13. 09 |
595 |
Updated Antiplatelet Therapy After PCI; Prasugrel, AZD6140..;The Future We Can Expect in Routine Practice? |
David Joel Cohen |
May. 13. 09 |
594 |
What Is the Optimal Duration of Dual Antiplatelet Therapy Following DES Treatment? |
David E. Kandzari |
May. 13. 09 |
593 |
Updated Data and Clinical Application of Triple Antiplatelet Therapy: The Answer to Patients with CYP 2C19 Polymorphism and High Post-Treatment Platelet Reactivity After Clopidogrel? |
Seung-Whan Lee |
May. 13. 09 |
592 |
Polymorphism in Metabolism of Clopidogrel and Its Clinical Implication and Management |
Alexandra J. Lansky |
May. 13. 09 |
591 |
Clopidogrel Response Variability and Platelet Function Testing: Should Routine Practice Be Changed in Interventional Cardiology? |
Matthew Price |
May. 13. 09 |
590 |
ASPIRE HIGHER: Are There Still Existing Unmet Needs? What We Expect from New Anti-Hypertensive Treatment |
Sang-Hong Baek |
Oct. 24. 08 |